{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:46:24Z","timestamp":1793490384801,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":636,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1136\/esmoopen-2020-000733","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T14:25:10Z","timestamp":1593613510000},"page":"e000733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"special_numbering":"S3","title":["New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis"],"prefix":"10.1016","volume":"4","clinical-trial-number":[{"clinical-trial-number":"nct02110082","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01775631","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02252263","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03318900","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03809624","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03792724","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-0836","authenticated-orcid":false,"given":"I\u00f1aki","family":"Etxeberria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-190X","authenticated-orcid":false,"given":"Javier","family":"Glez-Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2020-000733_bb0010","author":"Ribas"},{"key":"10.1136\/esmoopen-2020-000733_bb0015","author":"Kwon"},{"key":"10.1136\/esmoopen-2020-000733_bb0020","author":"Goodwin"},{"key":"10.1136\/esmoopen-2020-000733_bb0025","author":"Zapata"},{"key":"10.1136\/esmoopen-2020-000733_bb0030","author":"Cannons"},{"key":"10.1136\/esmoopen-2020-000733_bb0035","author":"Lee"},{"key":"10.1136\/esmoopen-2020-000733_bb0040","author":"Melero"},{"key":"10.1136\/esmoopen-2020-000733_bb0045","author":"Shuford"},{"key":"10.1136\/esmoopen-2020-000733_bb0050","author":"Menk"},{"key":"10.1136\/esmoopen-2020-000733_bb0055","author":"Teijeira"},{"key":"10.1136\/esmoopen-2020-000733_bb0060","author":"Aznar"},{"key":"10.1136\/esmoopen-2020-000733_bb0065","author":"Freeman"},{"key":"10.1136\/esmoopen-2020-000733_bb0070","author":"Choi"},{"key":"10.1136\/esmoopen-2020-000733_bb0075","author":"Kohrt"},{"key":"10.1136\/esmoopen-2020-000733_bb0080","author":"Kohrt"},{"key":"10.1136\/esmoopen-2020-000733_bb0085","author":"Ochoa"},{"key":"10.1136\/esmoopen-2020-000733_bb0090","author":"Wolfl"},{"key":"10.1136\/esmoopen-2020-000733_bb0095","author":"Ye"},{"key":"10.1136\/esmoopen-2020-000733_bb0100","author":"Sanchez-Paulete"},{"key":"10.1136\/esmoopen-2020-000733_bb0105","author":"Melero"},{"key":"10.1136\/esmoopen-2020-000733_bb0110","author":"Wilcox"},{"key":"10.1136\/esmoopen-2020-000733_bb0115","author":"Williams"},{"key":"10.1136\/esmoopen-2020-000733_bb0120","author":"Weigelin"},{"key":"10.1136\/esmoopen-2020-000733_bb0125","author":"Stephan"},{"key":"10.1136\/esmoopen-2020-000733_bb0130","author":"Buchan"},{"key":"10.1136\/esmoopen-2020-000733_bb0135","author":"Azpilikueta"},{"key":"10.1136\/esmoopen-2020-000733_bb0140","author":"Melero"},{"key":"10.1136\/esmoopen-2020-000733_bb0145","author":"Wei"},{"key":"10.1136\/esmoopen-2020-000733_bb0150","author":"Gros"},{"key":"10.1136\/esmoopen-2020-000733_bb0155","author":"Curran"},{"key":"10.1136\/esmoopen-2020-000733_bb0160","author":"Westwood"},{"key":"10.1136\/esmoopen-2020-000733_bb0165","author":"Lee"},{"key":"10.1136\/esmoopen-2020-000733_bb0170","author":"Souza-Fonseca-Guimaraes"},{"key":"10.1136\/esmoopen-2020-000733_bb0175","author":"Rodriguez-Ruiz"},{"key":"10.1136\/esmoopen-2020-000733_bb0180","author":"Quetglas"},{"key":"10.1136\/esmoopen-2020-000733_bb0185","author":"June"},{"key":"10.1136\/esmoopen-2020-000733_bb0190","author":"Zhao"},{"key":"10.1136\/esmoopen-2020-000733_bb0195","author":"Kawalekar"},{"key":"10.1136\/esmoopen-2020-000733_bb0200","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/jco.2008.26.15_suppl.3007","article-title":"Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (PTS) with advanced cancer (CA)","volume":"26","author":"Sznol","year":"2008","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2020-000733_bb0205","author":"Segal"},{"key":"10.1136\/esmoopen-2020-000733_bb0210","article-title":"Clinical safety and efficacy as- sessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies","volume":"239","author":"Massarelli","year":"2016","journal-title":"Proceeding of the 31st annual meeting and associated programs of the Society for immunotherapy of cancer"},{"key":"10.1136\/esmoopen-2020-000733_bb0215","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/jco.2014.32.15_suppl.3007","article-title":"A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer","volume":"32","author":"Segal","year":"2014","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2020-000733_bb0220","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/jco.2015.33.15_suppl.3004","article-title":"A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL","volume":"33","author":"Gopal","year":"2015","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2020-000733_bb0225","author":"Tolcher"},{"key":"10.1136\/esmoopen-2020-000733_bb0230","author":"Dubrot"},{"key":"10.1136\/esmoopen-2020-000733_bb0235","author":"Bartkowiak"},{"key":"10.1136\/esmoopen-2020-000733_bb0240","author":"Hinner"},{"key":"10.1136\/esmoopen-2020-000733_bb0245","series-title":"Phase 1 dose escalation study of PRS-343, a HER2\/4-1BB bispecific molecule, in patients with HER2+ malignancies","author":"Piha-Paul","year":"2019"},{"key":"10.1136\/esmoopen-2020-000733_bb0250","series-title":"Potent tumor-directed T cell activation and tumor inhibition induced by ALG.APV-527, a 4-1BB x 5T4 ADAPTIRTM bispecific antibody","author":"Nelson","year":"2019"},{"key":"10.1136\/esmoopen-2020-000733_bb0255","author":"Claus"},{"key":"10.1136\/esmoopen-2020-000733_bb0260","author":"Compte"},{"key":"10.1136\/esmoopen-2020-000733_bb0265","author":"Palaz\u00f3n"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920301101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920301101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2020-000733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:24Z","timestamp":1761855744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920301101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":52,"alternative-id":["S2059702920301101"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2020-000733","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2020-000733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000733"}}